Target intelligence / Profile preview

C-C motif chemokine ligand 28 (CCL28)

Target
CCL28
Molecular classification
Chemokine, Cytokine, C-C chemokine subfamily (β-chemokine)[2][4]
01

Overview

C-C motif chemokine ligand 28 (CCL28) is a member of the CC chemokine family, primarily expressed by epithelial cells in mucosal tissues such as the gut, lung, salivary glands, and breast. CCL28 acts as a chemoattractant for T and B lymphocytes expressing the CCR10 receptor and for eosinophils via CCR3, thereby orchestrating the mucosal recruitment and homing of immune cells. Aside from its chemotactic role, CCL28 has been shown to possess broad-spectrum antimicrobial activity against certain bacteria and fungi. It is constitutively present in mucosal secretions but can be upregulated in inflammation or infection, marking its importance in both innate and adaptive immunity. CCL28 is of growing interest as both a disease biomarker (notably in breast cancer) and a potential therapeutic target in infection, immune-related, and inflammatory conditions[1][2][3][4].

Other names
CCL28Mucosae-associated epithelial chemokineMECCCK1SCYA28Small-inducible cytokine A28Chemokine (C-C motif) ligand 28Protein CCK1Small inducible cytokine subfamily A (Cys-Cys), member 28[1][4]
02

Mechanism of action

Chemokine receptor modulation (drugs could modulate interaction with CCR10/CCR3, but none are currently approved) Immunomodulation (potential approach under investigation)[2]

03

Biological functions

Chemotaxis (directs the migration of T and B lymphocytes, especially those expressing CCR10, and eosinophils expressing CCR3)Immune response (involved in both innate and adaptive immunity)Antimicrobial activity (against Gram-positive bacteria, Gram-negative bacteria, and some fungi)Mucosal immunity (drives recruitment and homing of lymphocytes to mucosal/epithelial tissues)[1][2]
04

Disease associations

Infection (host immunity, antimicrobial defense)Inflammation (upregulated in response to pro-inflammatory cytokines and injury)Cancer (early evidence for biomarker role in triple-negative breast cancer)Autoimmunity (recruitment of regulatory T cells and immune tolerance)[1][2][4]
05

Safety considerations

Potential for disrupting mucosal immunity and tolerance if targetedPossible effects on susceptibility to infections or autoimmune reactions if CCL28 activity is manipulated[2]
06

Biomarkers

Preliminary evidence for CCL28 as a biomarker in triple-negative breast cancer and possibly in monitoring mucosal inflammation[4]

Beyond the preview

Go deeper on C-C motif chemokine ligand 28 (CCL28).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-C motif chemokine ligand 28 (CCL28).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call